Search
Menu
Home
HTB
2017
November
24
HTB
24 November 2017
Contents
Antiretrovirals
Coformulated dolutegravir plus rilpivirine approved in US (Juluca)
Darunavir-based single pill FDC approved in EU (Symtuza)
HTB RSS
Early access
UK biobank finds no link between CMV infection and cardiovascular disease: HIV not included in study
25 July 2021
RCT shows no impact of azithromycin in reducing symptoms of mild COVID-19
25 July 2021
Variation in ACE2 levels are not related to outcomes from COVID-19
25 July 2021
IAS 2021: lenacapavir studies show impressive results in naive, extensive drug resistance and potential as PrEP
20 July 2021
All early access reports
Current issues
July 2021
June 2021
May 2021
Back issues
Special report
HTB: no. 5 – plus HIV and COVID-19 (3 May 2021)
3 May 2021
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
